Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-031"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Variations to the terms of marketing authorisations for medicinal products - Counterfeiting of medicinal products (debate)2
dcterms:Language	"ro"^^xsd:language2
lpv:document identification number	"en.20081022.2.3-031"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-0322
lpv:speaker	lp:Cristian-Silviu Buşoi2
lpv:spokenAs	member; SEDE (2007-12-13--2009-07-13)3 substitute; Delegation for relations with the United States (2007-12-13--2009-07-13)3 member; Delegation for relations with the People's Republic of China (2007-12-13--2009-07-13)3 member; ALDE (2007-12-10--2009-07-13)3 unknown; Partidul Naţional Liberal (2007-12-10--2009-07-13)3 substitute; AFET (2007-12-12--2009-07-13)3 member; IMCO (2007-12-12--2009-07-13)3
lpv:translated text	"It is my firm belief that this draft directive marks significant progress in terms of speeding up access to medicines. I would also like to congratulate the Commission, Commissioner Verheugen and the rapporteur for this initiative. Given that the free circulation of goods is one of the basic principles of the internal market, it seems completely natural to me that this principle should apply to medicinal products as well. At the moment, due to the complexity and diversity of the administrative procedures for authorising variations made to medicines already on sale, the actual operation of the internal market is distorted. Of course, this situation affects the pharmaceutical industry and authorities, but it is patients who are primarily affected because these complex procedures delay them receiving the benefits of improved medicines. I therefore totally agree with the Commission’s proposal to harmonise the procedures for authorising variations made to medicines, regardless of the initial authorisation procedure, as this simplification will streamline the entire system and, above all, guarantee a higher level of public health protection. I also support the idea put forward by the rapporteur, Mrs Grossetête, concerning the need for a single procedure for authorising variations which will provide greater authority. With regard to the final remark concerning the Commission’s proposal to retain the medicine’s initial name in the event of extending authorisation, I support keeping the initial name, since frequently changing the names of medicines may confuse patients who need, in any case, to see a doctor before receiving any treatment, and the doctor will be up to date with the medicine’s new therapeutic indications."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph